Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer.
Masago
Katsuhiro
K
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Syogoin-Kawaracho, Sakyo-Ku, Kyoto 606-8507, Japan. masago@kuhp.kyoto-u.ac.jp
Fujita
Shiro
S
Mio
Tadashi
T
Togashi
Yosuke
Y
Kim
Young Hak
YH
Hatachi
Yukimasa
Y
Fukuhara
Akiko
A
Irisa
Kaoru
K
Sakamori
Yuichi
Y
Mishima
Michiaki
M
D000230:Adenocarcinoma / Q000097:blood / Q000401:mortality / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000990:Antithrombin III / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000097:blood*; D001777:Blood Coagulation; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000401:mortality / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000401:mortality / Q000628:therapy; D005260:Female; D005341:Fibrinolysin / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000378:metabolism*; D011379:Prognosis; D015996:Survival Rate; D000979:alpha-2-Antiplasmin / Q000378:metabolism*
D014408:Biomarkers, Tumor; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin